Oct. 29 Quick Takes: Ultragenyx, Scholar Rock, Galecto, Citrine-Bioprojet, miRagen-Viridian, Elpis, CASI-BioInvent
Ultragenyx, Scholar Rock offerings
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Scholar Rock Holding Corp. (NASDAQ:SRRK) raised follow-ons late Wednesday. Ultragenyx raised $400 million, while Scholar Rock raised $200 million via the shares and prefunded warrants after its stock more than doubled on Tuesday on interim spinal muscular atrophy Phase II data.
Galecto raises $85M in NASDAQ IPO
Galecto Inc. (NASDAQ:GLTO) raised $85 million through the sale of 5.7 million shares at $15 per share, the midpoint of its proposed range. The company has an idiopathic pulmonary fibrosis treatment in Phase II testing and two programs slated to begin Phase II testing by year-end for liver fibrosis related to non-alcoholic steatohepatitis and myelofibrosis. ...